CTLA4 and melanoma: TRAE spectra differ between patients receiving immunology as monotherapy or combined with ipilimumab (anti–CTLA-4); however, the immune-related AEs were similar to those after anti–PD-1/PD-L1 with or without ipilimumab in patients with advanced melanoma (Robert et al., 2015; Wolchok et al., 2015).